The United States Patent and Trademark Office (USPTO) has granted patent US12583910B2 to Tsinghua University. The patent covers a T cell antigen receptor (TCR) complex, antibodies or antigen-binding fragments thereof, immune cells expressing the TCR, and methods for their preparation and use. The claimed technology is designed to specifically recognize corresponding pMHC complexes, activate TCR T cells, produce cytokines such as IFNγ, IL2, and TNFα, kill target cells, and potentially extend the life of tumor-bearing mice.

This patent grant signifies the USPTO's recognition of novel intellectual property in the field of immunotherapy and cellular therapy. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on companies, it establishes exclusive rights for the assignee. Companies operating in the immunotherapy space, particularly those developing T cell-based therapies or related diagnostic tools, should be aware of this patent to avoid potential infringement and to inform their own research and development strategies. No specific compliance actions are mandated by this grant, but it may impact licensing agreements and competitive landscapes in the pharmaceutical and biotechnology sectors.